Biotechs target rare cancers to find lucrative markets

10/28/2005 | Forbes

Ariad Pharmaceuticals, like many biotech firms, once pursued drugs only for the largest markets but now is testing a drug, AP23573, aimed at a rare form of sarcoma diagnosed in only 12,000 to 13,000 patients a year. Other boutique firms focusing on rare disease are finding the cause may be narrowed to a single gene and the results can be successful and profitable when few other remedies exist.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA